OKYO Pharma Limited
OKYOHealthcare·Biotechnology·United Kingdom·Micro·NASD·Nov 11 • 3:59 PM ET
1.42+0.04 (2.90%)
2026-11-12 05:56 CET
Market cap
74.52 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-8.95 USD m
Free cash flow, TTM
-5.94 USD m
EPS diluted, TTM
-0.19
P/E
-
Price
OKYO against its 20, 50 and 200-day averages2050200miss
55.6% under the 52-week high of 3.20 on 14 Jan 2026. 52-week low 1.27 on 1 Oct 2026. Last 15 sessions, 19.9% high to low
Volume 0.90× normal · the line is the 50-bar volume average
Profile
OKYO52-week range, 8% of the way up
1.263.20
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.
| IPO | May 17, 2022 |
|---|---|
| Beta | 0.04 |
| ATR, 14d | 0.11 |
| Rel volume | 0.90 |
| Short float | 0.13% |
| Insider own | 32.09% |
| Inst own | 19.99% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 74.52M |
| Enterprise Value | 53.93M |
| Income | -8.95M |
| Sales | 0.00M |
| Book/sh | 0.24 |
| Cash/sh | 0.39 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | - |
| IPO | May 17, 2022 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | 6.04 |
| P/C | 3.62 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | 2.43 |
| Current Ratio | 2.43 |
| Debt/Eq | 0.00 |
| LT Debt/Eq | 0.00 |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | -0.19 |
|---|---|
| EPS next Y | -0.41 |
| EPS next Q | -0.04 |
| EPS this Y | 20.59% |
| EPS next Y | -200.00% |
| EPS next 5Y | - |
| EPS past 3/5Y | 26.21% -116.82% |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | -39.90% |
| Sales Y/Y TTM | - |
| EPS Q/Q | -115.28% |
| Sales Q/Q | - |
| Earnings | Jun 03 |
| EPS/Sales Surpr. | -87.50% - |
Ownership
| Insider Own | 32.09% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 19.99% |
| Inst Trans | 0.46% |
| ROA | -72.60% |
| ROE | -263.78% |
| ROIC | -72.55% |
| Gross Margin | - |
| Oper. Margin | - |
| Profit Margin | - |
| SMA20 | -0.91% |
| SMA50 | 0.01% |
| SMA200 | -10.30% |
| Trades | - |
Technical
| Shs Outstand | 52.48M |
|---|---|
| Shs Float | 35.64M |
| Short Float | 0.13% |
| Short Ratio | 0.69 |
| Short Interest | 0.05M |
| 52W High | 3.20 -55.63% |
| 52W Low | 1.26 12.27% |
| Volatility | 9.78% 7.24% |
| ATR (14) | 0.11 |
| RSI (14) | 49.64 |
| Beta | 0.04 |
| Rel Volume | 0.90 |
| Avg Volume | 66.35K |
| Volume | 59,881 |
Performance
| Perf Week | -0.70% |
|---|---|
| Perf Month | -1.22% |
| Perf Quarter | -5.96% |
| Perf Half Y | -12.35% |
| Perf YTD | -31.40% |
| Perf Year | -48.55% |
| Perf 3Y | -17.44% |
| Perf 5Y | - |
| Perf 10Y | - |
| Recom | 1.00 |
| Target Price | 6.00 |
| Prev Close | 1.38 |
| Price | 1.42 |
| Change % | 2.90% |
Analyst ratings
latest 2 of 2| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Feb 20, 2026 | Initiated | PPiper Sandler | Overweight | $7 | +393.0% |
| Dec 08, 2025 | Initiated | RB. Riley Securities | Buy | $5 | +252.1% |
Peers
Mkt capNews
latest 14 of 200- OKYO Pharma to Present at the Stifel 2026 Healthcare Conference (GlobeNewswire)
- OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug (Proactive)
- OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain (GlobeNewswire)
- OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences (GlobeNewswire)
- OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 (GlobeNewswire) -5.23%
- OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference (GlobeNewswire)
- OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer (GlobeNewswire)
- OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 (GlobeNewswire) +5.81%
- OKYO Pharma Announces Purchase of Shares by Director (GlobeNewswire)
- OKYO Pharma Announces Purchase of Shares by Chief Executive Officer (GlobeNewswire)
- OKYO Pharma Announces Purchase of Shares by Chairman (GlobeNewswire) +5.56%
- OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director (GlobeNewswire)
- OKYO Pharma Announces Purchase of Shares by Chief Medical Officer (GlobeNewswire)
- OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.11%
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2025S2 | 2026-06-03 | -0.150 | -0.080 | -0.170 | 0.00 | 0.00 | 1 |
| 2025S1 | 2025-12-03 | -0.010 | -0.070 | -0.069 | 0.00 | - | 1 |
| 2024S2 | 2025-08-05 | -0.050 | -0.050 | -0.056 | - | - | 1 |
| 2024S1 | 2024-11-29 | -0.080 | - | -0.080 | - | - | - |
| 2024Q1 | 2024-08-28 | -0.090 | -0.090 | - | 0.00 | 0.00 | 1 |
| 2023Q4 | 2024-07-30 | -0.090 | -0.090 | - | 0.00 | 0.00 | 1 |
| 2023Q3 | 2024-02-28 | -0.100 | -0.100 | - | 0.00 | 0.00 | 1 |
| 2023Q2 | 2023-11-29 | -0.110 | -0.110 | - | 0.00 | 0.00 | 1 |
| 2022S1 | 2022-12-30 | 0.000 | - | -0.004 | - | - | - |
| 2024Q3 | - | - | -0.100 | - | - | 0.00 | 1 |
| 2024Q4 | - | - | -0.100 | - | - | 0.00 | 1 |
| 2026S1 | - | - | -0.060 | - | - | 0.00 | 1 |
| 2026S2 | - | - | -0.060 | - | - | 0.00 | 1 |
| 2027S1 | - | - | -0.100 | - | - | 0.00 | 1 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2022FY | -0.610 | - | -0.596 | 0.00 | - |
| 2023FY | -0.400 | -0.400 | -0.573 | 0.00 | 0.00 |
| 2024FY | -0.120 | -0.150 | -0.119 | 0.00 | 0.00 |
| 2025FY | -0.170 | -0.100 | -0.240 | 0.00 | 0.00 |
| 2026FY | - | -0.135 | - | - | 0.00 |
| 2027FY | - | -0.405 | - | - | 11.00 |
| 2028FY | - | -0.590 | - | - | 32.20 |
| 2029FY | - | -0.290 | - | - | 55.20 |
| 2030FY | - | 0.200 | - | - | 90.80 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026S1 | S | 2026-07-17 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026S1 | S | 2026-02-19 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026S1 | R | 2026-09-11 | 1 | 0 | 0 | -0.15 | -0.15 | -0.15 |
| 2026S1 | R | 2026-07-17 | 1 | 1 | 0 | -0.15 | -0.15 | -0.15 |
| 2026S1 | R | 2026-02-19 | 1 | 0 | 0 | -0.16 | -0.16 | -0.16 |
| 2026S1 | E | 2026-09-11 | 1 | 0 | 0 | -0.06 | -0.06 | -0.06 |
| 2026S1 | E | 2026-07-17 | 1 | 1 | 0 | -0.06 | -0.06 | -0.06 |
| 2026S1 | E | 2026-02-19 | 1 | 0 | 0 | -0.09 | -0.09 | -0.09 |
| 2026S1 | E | 2025-11-06 | 1 | 0 | 0 | -0.14 | -0.14 | -0.14 |
| 2026S1 | E | 2025-11-05 | 1 | 0 | 0 | -0.14 | -0.14 | -0.14 |
| 2026S1 | E | 2025-11-04 | 1 | 0 | 0 | -0.14 | -0.14 | -0.14 |
| 2026S1 | E | 2025-11-03 | 1 | 0 | 0 | -0.14 | -0.14 | -0.14 |
| 2026S1 | E | 2025-11-02 | 1 | 0 | 0 | -0.14 | -0.14 | -0.14 |
| 2026S1 | E | 2025-11-01 | 1 | 0 | 0 | -0.14 | -0.14 | -0.14 |
Estimate history
| EPS, annual | -0.07 | -0.01 | -0.003 | -0.005 | -0.006 | -0.596 | -0.573 | -0.119 | -0.24 |
|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| EPS, quarterly | |||||||||
| Period | |||||||||
| Sales, annual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Sales, quarterly | |||||||||
| Period | |||||||||
| Shares, annual | 388.419 | 524.108 | 636.297 | 672.816 | 1374.415 | 25.519 | 33.336 | 36.021 | 52.48 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Shares, quarterly | |||||||||
| Period |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Gross Profit | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.00 |
| Selling, General and Administrative Excl. Other | 9.20 | 9.20 | 7.19 | 15.69 | 13.08 | 6.23 | 3.15 | 1.51 | 4.92 |
| Research and Development | 1.81 | 1.81 | 2.25 | 8.24 | 6.34 | 1.30 | 0.17 | 0.52 | 3.06 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -9.20 | -9.20 | -7.19 | -15.69 | -13.09 | -6.23 | -3.16 | -1.52 | -4.92 |
| Interest Expense | 0.44 | 0.47 | 0.88 | 1.05 | 0.10 | - | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.13 | 0.00 |
| Net Income Before Taxes | -8.94 | -8.94 | -7.97 | -16.80 | -13.28 | -6.22 | -3.37 | -1.62 | -4.93 |
| Income Taxes | 0.01 | 0.01 | -3.26 | 0.02 | -0.01 | -0.79 | -0.02 | -0.08 | 0.00 |
| Consolidated Net Income | -8.95 | -8.95 | -4.71 | -16.83 | -13.27 | -5.43 | -3.35 | -1.54 | -4.94 |
| Net Income From Continuing Operations | -8.95 | -8.95 | -4.71 | -16.83 | -13.27 | -5.43 | -3.35 | -1.54 | -4.94 |
| Net Income | -8.95 | -8.95 | -4.71 | -16.83 | -13.27 | -5.43 | -3.35 | -1.54 | -4.94 |
| EPS (Recurring) | -0.17 | -0.24 | -0.12 | -0.57 | -0.60 | -0.01 | -0.00 | -0.00 | -0.01 |
| EPS (Basic, Before Extraordinaries) | -0.19 | -0.24 | -0.12 | -0.57 | -0.60 | -0.01 | -0.01 | -0.00 | -0.01 |
| EPS (Diluted) | -0.19 | -0.24 | -0.12 | -0.57 | -0.60 | -0.01 | -0.01 | -0.00 | -0.01 |
| EBITDA | -9.20 | -9.20 | -7.19 | -15.69 | -13.08 | -6.23 | -3.15 | -1.51 | -4.92 |
| Non-Operating Income (Expense) | 0.70 | 0.73 | 0.10 | -0.06 | -0.10 | 0.01 | -0.20 | 0.03 | -0.02 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Stock Option Compensation Expense | 1.20 | 1.20 | 0.55 | 0.84 | 0.96 | 1.43 | 0.42 | 0.06 | 0.08 |
| Shares Outstanding | 52.48 | 52.48 | 36.02 | 33.34 | 25.52 | 1,374.42 | 672.82 | 636.30 | 524.11 |
| Market Capitalization | 74.52 | 74.52 | 43.04 | 38.02 | 38.02 | - | - | - | - |
Income statement, quarterly
| Metric | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S1 | 2022S1 | 2021S2 | 2021S1 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Gross Profit | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | -0.02 |
| Selling, General and Administrative Excl. Other | 6.41 | 2.79 | 4.18 | 3.01 | 8.71 | 5.55 | 3.45 | 2.76 |
| Research and Development | 1.85 | -0.04 | 0.04 | 2.22 | 4.60 | 2.60 | 0.82 | 0.48 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -6.41 | -2.79 | -4.18 | -3.01 | -8.71 | -5.55 | -3.45 | -2.78 |
| Interest Expense | 0.36 | 0.08 | 0.12 | 0.76 | - | 0.00 | - | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -6.35 | -2.59 | -3.87 | -4.10 | -8.73 | -5.53 | -3.47 | -2.74 |
| Income Taxes | 0.01 | 0.00 | -1.85 | -1.42 | 0.08 | 0.00 | -0.59 | -0.19 |
| Consolidated Net Income | -6.36 | -2.59 | -2.03 | -2.68 | -8.82 | -5.53 | -2.88 | -2.55 |
| Net Income From Continuing Operations | -6.36 | -2.59 | -2.03 | -2.68 | -8.82 | -5.53 | -2.88 | -2.55 |
| Net Income | -6.36 | -2.59 | -2.03 | -2.68 | -8.82 | -5.53 | -2.88 | -2.55 |
| EPS (Recurring) | -0.12 | -0.07 | -0.06 | -0.08 | -0.34 | -0.00 | -0.00 | -0.00 |
| EPS (Basic, Before Extraordinaries) | -0.12 | -0.07 | -0.06 | -0.08 | -0.34 | -0.00 | -0.00 | -0.00 |
| EPS (Diluted) | -0.12 | -0.07 | -0.06 | -0.08 | -0.34 | -0.00 | -0.00 | -0.00 |
| EBITDA | -6.41 | -2.79 | -4.18 | -3.01 | -8.71 | -5.55 | -3.45 | -2.76 |
| Non-Operating Income (Expense) | 0.41 | 0.29 | 0.43 | -0.33 | -0.03 | 0.02 | -0.02 | 0.04 |
| Stock Option Compensation Expense | 0.79 | 0.41 | 0.24 | 0.31 | 0.44 | 0.55 | 0.74 | 0.69 |
| Shares Outstanding | 52.48 | 38.45 | 36.02 | 33.94 | 20.23 | 1,415.04 | 1,374.42 | 970.69 |
| Market Capitalization | 74.52 | 75.22 | 43.04 | 34.56 | 47.21 | 47.21 | - | - |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 20.59 | 1.56 | 0.83 | 4.05 | 2.71 | 6.89 | 0.24 | 0.63 | 2.82 |
| Short Term Receivables | 0.17 | 1.89 | 0.58 | 0.98 | 0.89 | 0.08 | 0.33 | 0.11 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.21 | 0.23 | 0.13 | 0.17 | 0.71 | 0.02 | 0.01 | 0.02 | 0.00 |
| Total Current Assets | 20.97 | 3.68 | 1.54 | 5.20 | 4.30 | 6.98 | 0.57 | 0.76 | 2.82 |
| Net Property, Plant & Equipment | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.10 | 0.03 | 0.00 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 20.98 | 3.68 | 1.54 | 5.20 | 4.31 | 7.09 | 0.60 | 0.76 | 2.82 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 2.22 | 0.00 | 0.03 | 0.01 | 0.00 | 0.00 |
| Accounts Payable | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 8.64 | 9.23 | 7.42 | 5.04 | 1.36 | 1.67 | 0.71 | 0.43 | 0.13 |
| Total Current Liabilities | 8.64 | 9.23 | 7.42 | 7.26 | 1.36 | 1.71 | 0.71 | 0.43 | 0.13 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.03 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 8.64 | 9.23 | 7.42 | 7.26 | 1.36 | 1.77 | 0.74 | 0.43 | 0.13 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 12.34 | -5.55 | -5.88 | -2.05 | 2.95 | 5.32 | -0.14 | 0.33 | 2.69 |
| Total Shareholders Equity | 12.34 | -5.55 | -5.88 | -2.05 | 2.95 | 5.32 | -0.14 | 0.33 | 2.69 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 12.34 | -5.55 | -5.88 | -2.05 | 2.95 | 5.32 | -0.14 | 0.33 | 2.69 |
| Total Liabilities & Stockholders Equity | 20.98 | 3.68 | 1.54 | 5.20 | 4.31 | 7.09 | 0.60 | 0.76 | 2.82 |
| Book Value Per Share | 0.24 | -0.15 | -0.18 | -0.08 | 0.00 | 0.01 | -0.00 | 0.00 | 0.01 |
| Tangible Book Value Per Share | 0.24 | -0.15 | -0.18 | -0.08 | 0.00 | 0.01 | -0.00 | 0.00 | 0.01 |
| Price to Book Ratio | 6.04 | -5.96 | - | - | - | - | - | - | - |
| Return on Assets | -72.60 | -180.37 | -498.89 | -279.01 | -95.30 | -87.06 | -227.13 | -276.04 | -74.53 |
| Return on Equity | -263.78 | - | - | -2,948.14 | -131.33 | -129.27 | -1,600.67 | -326.65 | -74.89 |
| Return on Invested Capital | -72.55 | - | - | - | -183.89 | -62.18 | - | -1,482.85 | -993.25 |
| Quick Ratio | 2.43 | 0.40 | 0.21 | 0.72 | 3.17 | 4.09 | 0.80 | 1.78 | 22.05 |
| Current Ratio | 2.43 | 0.40 | 0.21 | 0.72 | 3.17 | 4.09 | 0.80 | 1.78 | 22.05 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -8.94 | -8.94 | -7.97 | -16.80 | -13.28 | -6.22 | -3.37 | -1.62 | -4.94 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Other Funds (Non Cash) | 1.68 | 1.68 | 2.53 | 4.64 | 1.44 | 1.80 | 0.69 | 0.09 | 2.75 |
| Funds from Operations | -7.26 | -7.26 | -5.44 | -12.16 | -11.84 | -4.41 | -2.67 | -1.52 | -2.18 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 1.32 | 1.32 | 3.63 | 2.67 | 4.14 | -1.02 | 1.04 | 0.17 | 0.18 |
| Cash from Operating Activities | -5.94 | -5.94 | -1.81 | -9.49 | -7.70 | -5.44 | -1.63 | -1.35 | -2.00 |
| Capital Expenditures | -0.01 | -0.01 | -0.00 | 0.00 | -0.01 | -0.00 | -0.01 | 0.00 | -0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | -6.00 | -6.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Purchase of Investments | -6.00 | -6.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -6.01 | -6.01 | -0.00 | 0.00 | -0.01 | -0.00 | -0.02 | 0.00 | -0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 25.02 | 25.02 | 1.71 | 6.21 | 7.32 | 1.43 | 7.92 | 0.99 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 25.02 | 25.02 | 1.71 | 6.21 | 7.32 | 1.43 | 7.92 | 0.99 | 0.00 |
| Proceedsfrom Stock Options | 25.02 | 25.02 | 1.71 | 6.21 | 7.32 | 1.43 | 7.92 | 0.99 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.95 | 0.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.95 | 0.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.95 | 0.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 25.02 | 25.02 | 2.66 | 6.21 | 9.32 | 1.43 | 7.91 | 0.98 | 0.00 |
| Exchange Rate Effect | -0.05 | -0.05 | -0.11 | 0.06 | -0.28 | - | - | - | - |
| Net Change in Cash | 13.03 | 13.03 | 0.73 | -3.22 | 1.34 | -4.01 | 6.27 | -0.37 | -2.00 |
| Free Cash Flow | -5.94 | -5.94 | -1.81 | -9.49 | -7.70 | -5.44 | -1.63 | -1.35 | -2.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S1 | 2022S1 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 20.59 | 4.22 | 1.56 | 0.99 | 1.62 | 0.71 |
| Short Term Receivables | 0.17 | 0.02 | 1.89 | 1.52 | 0.50 | 0.54 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.21 | 0.40 | 0.23 | 0.32 | 0.26 | 0.52 |
| Total Current Assets | 20.97 | 4.64 | 3.68 | 2.83 | 2.37 | 1.77 |
| Net Property, Plant & Equipment | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 20.98 | 4.64 | 3.68 | 2.83 | 2.38 | 1.77 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.19 | 0.00 | 0.00 | 2.37 | 0.00 |
| Accounts Payable | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 8.64 | 7.87 | 9.23 | 10.05 | 5.94 | 2.12 |
| Total Current Liabilities | 8.64 | 8.06 | 9.23 | 10.05 | 8.32 | 2.12 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 8.64 | 8.06 | 9.23 | 10.05 | 8.32 | 2.12 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 12.34 | -3.42 | -5.55 | -7.23 | -5.94 | -0.35 |
| Total Shareholders Equity | 12.34 | -3.42 | -5.55 | -7.23 | -5.94 | -0.35 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 12.34 | -3.42 | -5.55 | -7.23 | -5.94 | -0.35 |
| Total Liabilities & Stockholders Equity | 20.98 | 4.64 | 3.68 | 2.83 | 2.38 | 1.77 |
| Book Value Per Share | 0.24 | -0.09 | -0.15 | -0.21 | -0.29 | -0.00 |
| Tangible Book Value Per Share | 0.24 | -0.09 | -0.15 | -0.21 | -0.29 | -0.00 |
| Price to Book Ratio | 6.04 | -12.98 | -5.96 | - | - | - |
| Return on Assets | -72.60 | -123.47 | - | - | - | -227.15 |
| Return on Equity | -263.78 | - | - | - | - | -364.19 |
| Return on Invested Capital | -51.58 | - | - | - | - | - |
| Quick Ratio | 2.43 | 0.58 | 0.40 | 0.28 | 0.29 | 0.83 |
| Current Ratio | 2.43 | 0.58 | 0.40 | 0.28 | 0.29 | 0.83 |
Cash flow, quarterly
| Metric | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S1 | 2022S1 |
|---|---|---|---|---|---|---|
| Net Income | -6.35 | -2.59 | -3.87 | -4.10 | -8.73 | -5.53 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Funds (Non Cash) | 1.14 | 0.54 | 1.66 | 0.87 | 0.48 | 0.81 |
| Funds from Operations | -5.21 | -2.05 | -2.21 | -3.23 | -8.25 | -4.72 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.81 | 0.52 | 0.64 | 2.99 | 1.46 | 1.19 |
| Cash from Operating Activities | -4.41 | -1.53 | -1.57 | -0.24 | -6.79 | -3.53 |
| Capital Expenditures | -0.01 | 0.00 | -0.00 | 0.00 | 0.00 | -0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -6.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | -6.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -6.01 | 0.00 | -0.00 | 0.00 | 0.00 | -0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 20.71 | 4.32 | 1.71 | 0.00 | 4.00 | 2.43 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 20.71 | 4.32 | 1.71 | 0.00 | 4.00 | 2.43 |
| Proceedsfrom Stock Options | 20.71 | 4.32 | 1.71 | 0.00 | 4.00 | 2.43 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.40 | 0.55 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.40 | 0.55 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.40 | 0.55 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | -0.63 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.63 |
| Cash from Financing Activities | 20.71 | 4.32 | 2.10 | 0.55 | 4.00 | 1.80 |
| Exchange Rate Effect | 0.08 | -0.13 | 0.04 | -0.15 | 0.36 | - |
| Net Change in Cash | 10.37 | 2.66 | 0.57 | 0.16 | -2.43 | -1.73 |
| Free Cash Flow | -4.41 | -1.53 | -1.57 | -0.24 | -6.79 | -3.53 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 0.13% | 0.0M | 35.6M | 66.07K |
| 2026-10-15 | 0.22% | 0.1M | 35.6M | 83.37K |
| 2026-09-30 | 0.10% | 0.0M | 35.6M | 107.33K |
| 2026-09-15 | 0.12% | 0.0M | 35.6M | 106.00K |
| 2026-08-31 | 0.15% | 0.1M | 35.6M | 100.67K |
| 2026-08-14 | 0.24% | 0.1M | 35.3M | 99.03K |
| 2026-07-31 | 0.38% | 0.1M | 35.3M | 96.08K |
| 2026-07-15 | 0.12% | 0.0M | 35.4M | 79.75K |
| 2026-06-30 | 0.09% | 0.0M | 34.6M | 67.08K |
| 2026-06-15 | 0.24% | 0.1M | 34.6M | 72.60K |
| 2026-05-29 | 0.36% | 0.1M | 34.9M | 82.15K |
| 2026-05-15 | 0.46% | 0.2M | 35.0M | 131.05K |
| 2026-04-30 | 0.75% | 0.3M | 35.0M | 185.43K |
| 2026-04-15 | 0.92% | 0.3M | 29.6M | 240.60K |
| 2026-03-31 | 0.70% | 0.2M | 29.6M | 269.83K |
| 2026-03-13 | 0.93% | 0.3M | 29.6M | 261.15K |
| 2026-02-27 | 1.47% | 0.4M | 29.6M | 273.75K |
| 2026-02-13 | 2.13% | 0.5M | 23.4M | 240.09K |
| 2026-01-30 | 1.29% | 0.3M | 22.5M | 194.48K |
| 2026-01-15 | 0.71% | 0.2M | 22.5M | 161.80K |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-05 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-11-05 | SEC |
| 2026-10-06 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-06 | SEC |
| 2026-09-29 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-29 | SEC |
| 2026-09-09 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-09 | SEC |
| 2026-09-08 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-08 | SEC |
| 2026-08-07 | 20-F/A | 2026-03-31 | SEC | |
| 2026-08-07 | 4/A | 2026-07-21 | SEC | |
| 2026-08-07 | 4/A | 2026-07-22 | SEC | |
| 2026-08-07 | 4/A | 2026-07-21 | SEC | |
| 2026-08-07 | 4/A | 2026-07-20 | SEC | |
| 2026-08-07 | 4/A | 2026-07-27 | SEC | |
| 2026-08-07 | 4/A | 2026-07-21 | SEC | |
| 2026-08-07 | 4/A | 2026-07-21 | SEC | |
| 2026-07-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-27 | SEC |
| 2026-07-29 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-07-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-28 | SEC |
| 2026-07-27 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-27 | SEC |
| 2026-07-23 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-22 | SEC |
| 2026-07-23 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-21 | SEC |
| 2026-07-23 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-21 | SEC |
| 2026-07-23 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-21 | SEC |
| 2026-07-23 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-23 | SEC |
| 2026-07-23 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-23 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-21 | SEC |
| 2026-07-22 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-22 | SEC |
| 2026-07-22 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-22 | SEC |
| 2026-07-22 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-22 | SEC |
| 2026-07-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-20 | SEC |
| 2026-07-21 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-21 | SEC |
| 2026-07-21 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-21 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| Woodline Partners LP | 7.11% |
| Stonepine Capital Management, LLC | 1.68% |
| Maven Securities LTD | 1.58% |
| BALYASNY ASSET MANAGEMENT L.P. | 1.13% |
| Opaleye Management Inc. | 0.73% |
| XTX Topco Ltd | 0.07% |
| Quantinno Capital Management LP | 0.06% |
| CHOREO, LLC | 0.06% |
| Cerity Partners LLC | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.02% |
Funds
| Fund | % owned |
|---|---|
| - | |
OakChart. OKYO. Cached 15 minutes.
Some panels did not load: insider.